RxDoctor Payments Data

John Bryant, MD

Urology · Cheyenne, WYNPI 1346328556

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,595 of the $7,813 with a category attached, or 84.4%. It is spread thinly across 43 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,173 and has fallen 54.3% since, to $993 in 2025.

$7,813in general payments, 2019–2025

Across 329 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Teleflex LLC$1K
  • Johnson & Johnson$705
  • Sumitomo Pharma America, Inc.$579
  • Bayer$447
  • Pfizer$404
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$5737%
  • Food & beverage$6,59584%
  • Education$6448%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$683,069
Medicare patients
1,259
Services billed
23,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide31$394,150
ErleadaApalutamide13$183,571
OrgovyxRelugolix22$67,718
MyrbetriqMirabegron24$14,534
Tamsulosin Hcl640$13,112
GemtesaVibegron11$10,751
Finasteride242$3,251
Dutasteride58$2,001
Potassium Citrate ErPotassium Citrate12$1,421
Alfuzosin Hcl ErAlfuzosin Hcl60$1,281
Bicalutamide20$273
Tadalafil12$256
Cephalexin56$239
Doxycycline Hyclate14$213
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,112$408,68455 claims
Johnson & JohnsonErleada$705$183,57113 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$579$78,46933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other urology in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →